Q&A

Clinical Supply Planning For Studies With Unconventional Timelines

Source: Catalent
gettyimages-1214329781-170667a

As a result of the industry's ongoing desire to save time, reduce costs, and get therapeutics to market as quickly and safely as possible, more drug sponsors are considering the advantages of conducting studies that deviate from standard timelines, including combined phases and adaptive designs. ‚ÄčIn this Q&A, Rajeev Daniel, Regional Manager, Clinical Supply Management at Catalent, discusses how these unconventional trials impact the supply chain, the role a CDMO can play in facilitating these trials, and the possible risks of such studies.

VIEW THE Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader